Lowering Homocysteine in Patients with Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial

JAMA

Volumn 291, Issue 5, 2004, Pages 565-575

  Toole, James F ^a   Malinow, M René ^b   Chambless, Lloyd E ^c   Spence, J David ^d   Pettigrew, L Creed ^e   Howard, Virginia J ^f   Sides, Elizabeth G ^a   Wang, Chin Hua ^c   Stampfer, Meir ^g  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF KENTUCKY   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; CYANOCOBALAMIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK REDUCTION; VITAMIN INTAKE; BLOOD; CORONARY ARTERY DISEASE; MIDDLE AGED; MULTICENTER STUDY; RISK; TREATMENT OUTCOME;

ADULT; AGED; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; RISK; TREATMENT OUTCOME; VITAMIN B 12; VITAMIN B 6;

EID: 1342309318     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.5.565     Document Type: Article

References (45)

1. Carson NA, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child. 1962;37:505-513.
2. Gerritsen T, Vaughn JG, Waisman HA. The identification of homocystine in the urine. Biochem Biophys Res Commun. 1962;9:493-496.
3. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-128.
4. Boers GH, Smals AG, Trijbels FJ, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985; 313:709-715.
5. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
6. Brattstrom LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia - a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke. 1984;15: 1012-1016.
7. Brattstrom L, Lindgren A, Israelsson B, et al. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest. 1992;22:214-221.
8. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke. 1990;21:572-576.
9. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
10. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994;25:1924-1930.
11. Yoo JH, Chung CS, Kang SS. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke. 1998;29:2478-2483.
12. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997; 277:1775-1781.
13. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
14. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131:363-375.
15. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
16. Boysen G, Brander T, Christensen H, Gideon R, Truelsen T. Homocysteine and risk of recurrent stroke. Stroke. 2003;34:1258-1261.
17. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
18. Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev. 1996;54:1-30.
19. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 1999;99:1156-1160.
20. van den Berg M, Boers GH, Franken DG, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 1995;25:176-181.
21. Leerink CB, van Ham AD, Heeres A, Duif PF, Bouma BN, van Rijn HJ. Sulfhydryl compounds influence immunoreactivity, structure and functional aspects of lipoprotein(a). Thromb Res. 1994;74:219-232.
22. Brattstrom L. Vitamins as homocysteine-lowering agents. J Nutr. 1996;126(suppl):1276S-1280S.
23. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet. 1998;351:263.
24. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. JAMA. 2002; 288:973-979.
25. Spence JD, Howard VJ, Chambless LE, et al. Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design. Neuroepidemiology. 2001;20:16-25.
26. Howard VJ, Sides EG, Newman GC, et al, for the Stability of Plasma Homocyst(e)ine in Acute Stroke Patients (SHASP) Study Investigators. Changes in plasma homocyst(e)ine in the acute phase after stroke. Stroke. 2002;33:473-478.
27. Mudd SH, Levy HL. Plasma homocyst(e)ine or homocysteine? N Engl J Med. 1995;333:325.
28. D'Olhaberriague L, Litvan I, Mitsias P, et al. A reappraisal of reliability and validity studies in stroke. Stroke. 1996;27:2331-2336.
29. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
30. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ. 1962;27:645-658.
31. Smolin LA, Schneider JA. Measurement of total plasma cysteamine using high-performance liquid chromatography with electrochemical detection. Anal Biochem. 1988;168:374-379.
32. Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989; 79:1180-1188.
33. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)ine in daily practice: levels in coronary artery disease. Coron Artery Dis. 1990;1:215-220.
34. Piantadosi S. Clinical Trials: A Methodologic Perspective. New York, NY: John Wiley & Sons; 1977.
35. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin Niacin, Vitamin B6, Folate, Vitamin B12, Panothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press; 1988.
36. Hospital & Payer International Classification of Diseases, Ninth Revision, Clinical Modification. 5th ed. Salt Lake City, Utah: Medicode Publications; 1999.
37. Halperin M, Lan KK, Ware JH, Johnson NJ, DeMets DL. An aid to data monitoring in long-term clinical trials. Control Clin Trials. 1982;3:311-323.
38. Lan KK, Wittes J. The B-value: a tool for monitoring data. Biometrics. 1988;44:579-585.
39. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
40. Nygård O, Nordehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
41. Graham IM, Daly L, Refsum H, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA. 1997;277:1775-1781.
42. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202.
43. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.
44. Stampfer MJ, Malinow MR, Willet WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992; 268:877-881.
45. Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial. Circulation. 2002;106(suppl):II741S.